Περίληψη:
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast
cancer (BC) and accounts for 10-20% of cases. Due to the lack of
expression of several receptors, hormone therapy is largely ineffective
for treatment purposes. Nevertheless, TNBC often responds very well to
chemotherapy, which constitutes the most often recommended treatment.
New beneficial targeted therapies are important to be investigated in
order to achieve enhanced outcomes in patients with TNBC. This review
will focus on recent therapeutic innovations for TNBC, focusing on
various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway
inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase
inhibitors, histone deacetylase inhibitors (HDACIs), and immune
checkpoint inhibitors.
Συγγραφείς:
Damaskos, Christos
Garmpis, Nikolaos
Garmpi, Anna and
Nikolettos, Konstantinos
Sarantis, Panagiotis
Georgakopoulou,
Vasiliki E.
Nonni, Afroditi
Schizas, Dimitrios
Antoniou,
Efstathios A.
Karamouzis, V, Michalis
Nikolettos, Nikos and
Kontzoglou, Konstantinos
Patsouras, Alexandros
Voutyritsa,
Errika
Syllaios, Athanasios
Koustas, Evangelos
Trakas,
Nikolaos
Dimitroulis, Dimitrios
